Yale Bulletin and Calendar

April 21, 2006|Volume 34, Number 27|Two-Week Issue


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Five-year grant supports surgeon's work to develop tissue-engineered blood vessels

A School of Medicine surgeon who is developing techniques to grow replacement blood vessels from a patient's own cells is the recipient of a five-year grant from the National Heart, Lung and Blood Institute.

The $625,000 grant to Dr. Christopher Breuer, assistant professor in the Departments of Surgery and Pediatrics, is for his research to develop tissue-engineered blood vessels for those suffering from serious cardiovascular diseases.

About 35,000 pediatric cardiovascular operations are performed in the United States annually. Most operations are performed using bioprosthetic vascular grafts. These are arteries taken from another person and specially processed so that they can be transplanted into the recipient and not be rejected by the body. The durability and longevity of these grafts are limited because the arteries are not alive and therefore cannot remodel or repair themselves over time.

Approximately 75,000 adults per year undergo bypass surgery for either severe coronary artery disease or peripheral vascular disease. It is estimated that an additional 80,000 patients per year are unable to undergo life- or limb-saving surgeries due to the inadequacies of currently available blood vessel grafts. The ability to create a tissue-engineered vascular graft has the potential to help these patients.

In tissue-engineered blood vessels, cells are taken from a patient and put in an incubator, where they grow and reproduce. Cells are recovered from this culture and placed on a biodegradable synthetic matrix that acts as a three-dimensional scaffold. The matrix is made of polyglycolic acid, the same material used to produce absorbable sutures. The cells on the matrix reproduce and develop into tissue, while the matrix itself gradually degrades over a period of six weeks.

Breuer says his laboratory currently is studying the use of this technology to create vascular grafts for both pediatric and adult cardiovascular operations. Current investigations are evaluating the use of advanced drug delivery technology and genetic engineering methods to optimize graft function.

-- By Jacqueline Weaver


T H I SW E E K ' SS T O R I E S

University will review its Special Student Program

Thirteen are honored for their work promoting town-gown cooperation

Hu's speech to be broadcast, web-streamed

A lesson in egg-drop engineering

YALE & CHINA: HISTORIC TIES, EXPANDING PARTNERSHIPS

Symposium honors centennial of astronomy researcher

UAE minister speaks with Yale officials, students . . .

Foreign-language and self-guided audio tours of Yale campus . . .

Research demonstrates that neurons in brain communicate . . .

Symposium on 'Rethinking Historicism' honors Annabel Patterson

Peptide that functions like a nanosyringe offers new tool for drug delivery

Research clarifies how animals perceive environmental odors

In Memoriam: William Sloane Coffin Jr.

Graduating nursing student awarded Nightingale Scholarship

Yale Opera production will feature works by German composers

Next Dean's Workshop will explore flow cytometry research

Center to mark anniversary of city's Holocaust Memorial

Five-year grant supports surgeon's work to develop . . .

Event to celebrate students' written stories about their nursing experiences

Campus Notes

Correction


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home